Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone versus pegylated liposomal doxorubicin in platinum/taxane-refractory or -resistant recurrent ovarian-related cancer
2004-005181-20Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of patupilone in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Novartis. Started Nov 2005; status: completed.
02
Drugs
patupilone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2004-005181-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005181-20.